公开(公告)号：US20240252497A1

公开(公告)日：2024-08-01

申请号：US18564202

申请日：2022-05-26

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Aleksandar Skuban ,  Mingjun Huang ,  David Boyer ,  Jose Rivera ,  Ya-Ping Ko ,  Xiang Gao

IPC: A61K31/506 ,  A61P27/02

CPC classification number: A61K31/506 ,  A61P27/02

Abstract: Disclosed herein are methods for treating geographic atrophy secondary to age-related macular degeneration (AMD) and intermediate AMD in a subject. The methods include administering to the subject a therapeutically effective amount of a small molecule complement factor D inhibitor.

公开(公告)号：US20230235035A1

公开(公告)日：2023-07-27

申请号：US18011807

申请日：2021-07-08

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Lori Payton ,  Scott T. Rottinghaus ,  Rajendra Pradhan ,  Stephan Ortiz ,  Masayo Ogawa ,  Xiang Gao

IPC: C07K16/18 ,  A61P7/00

CPC classification number: C07K16/18 ,  A61P7/00 ,  A61K2039/545

Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in pediatric patients using an anti-C5 antibody, or antigen binding fragment thereof.

公开(公告)号：US12128101B2

公开(公告)日：2024-10-29

申请号：US16757512

申请日：2018-10-26

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Lori Payton ,  Scott T. Rottinghaus ,  Rajendra Pradhan ,  Andrew Damokosh ,  Xiang Gao

IPC: A61K39/395 ,  A61K9/00 ,  A61K39/00 ,  A61P7/00 ,  C07K16/18

CPC classification number: A61K39/3955 ,  A61K9/0019 ,  A61P7/00 ,  C07K16/18 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/92

Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.

公开(公告)号：US20220235121A1

公开(公告)日：2022-07-28

申请号：US17424794

申请日：2020-01-24

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Lori Payton ,  Christian Mix ,  Rajendra Pradhan ,  Andrew Damokosh ,  Eugene Scott Swenson ,  Xiang Gao

IPC: C07K16/18

Abstract: Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.

公开(公告)号：US11229686B2

公开(公告)日：2022-01-25

申请号：US15760656

申请日：2016-09-27

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Rajendra Pradhan ,  Xiang Gao

IPC: A61P19/08 ,  A61K38/46 ,  A61K9/00 ,  A61P3/00 ,  A61K38/00

Abstract: A method of treating a human having a condition or disease related to a bone defect characterized by at least one of: increased level of an alkaline phosphatase ligand, particularly PPi, PLP, or PEA; and decreased alkaline phosphatase activity, compared to a human without said condition or disease, comprising administering to the human a therapeutically effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, wherein the polypeptide is administered through at least one subcutaneous injection to the human in a frequency of fewer than three times each week.

公开(公告)号：US20210395352A1

公开(公告)日：2021-12-23

申请号：US17289178

申请日：2019-10-30

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Lori Volles ,  Rajendra Pradhan ,  Douglas L. Sheridan ,  Marc Vallee ,  Xiang Gao

IPC: C07K16/18 ,  A61P7/00

Abstract: Provided are methods for clinical treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (Soliris®).

公开(公告)号：US20230346784A1

公开(公告)日：2023-11-02

申请号：US18022330

申请日：2021-08-27

Applicant: Alexion Pharmaceuticals, Inc. ,  The Johns Hopkins University

Inventor： Moshe Vardi ,  Robert A. Brodsky ,  Xiang Gao ,  Shamsah D. Kazani ,  Venu Nagali ,  Xuan Yuan

IPC: A61K31/506 ,  A61K31/675 ,  A61K45/06 ,  A61K31/727 ,  A61P31/14 ,  G01N33/50

CPC classification number: A61K31/506 ,  A61K31/675 ,  A61K45/06 ,  A61K31/727 ,  A61P31/14 ,  G01N33/5091 ,  G01N2800/56 ,  G01N2800/52 ,  G01N2333/4716

Abstract: The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection. Also provided are methods of treating an infection by a betacoronavirus, e.g., SARS-CoV, MERS-CoV, or SARS-CoV-2, in a human subject. The methods of treatment include administering to the human subject a therapeutically effective amount of at least one complement factor D inhibitor. Also provided herein are compounds for treating an infection by a betacoronavirus and their use in the manufacture in a medicament for treating an infection by a betacoronavirus.

公开(公告)号：US20230416344A1

公开(公告)日：2023-12-28

申请号：US17918863

申请日：2021-04-16

Applicant: Alexion Pharmaceuticals, Inc. ,  Assistance Publique, Hopitaux de Paris ,  Djillali Annane ,  Veronique Fremeaux-Bacchi ,  Regis Peffault De Latour

Inventor： Sharon Barr ,  Derek Dunn ,  Xiang Gao ,  Shamsah D. Kazani ,  Michele Mercuri ,  Jonathan Monteleone ,  Stephan Ortiz ,  Scott T. Rottinghaus ,  Martine Zimmermann ,  Djillali Annane ,  Veronique Fremeaux-Bacchi ,  Regis Peffault De Latour

IPC: C07K16/18 ,  A61K45/06 ,  A61P31/14 ,  G01N33/569

CPC classification number: C07K16/18 ,  A61K45/06 ,  A61P31/14 ,  G01N2469/20 ,  C07K2317/76 ,  C07K2317/24 ,  G01N33/56983

Abstract: The present disclosure relates to, inter alia, a method of treating a complement mediated disorder caused by a virus, e.g., corona virus; Dengue virus (DENY); Ross River vims (RRV) and/or influenza virus (flu) by administering an effective amount of a complement modulator, such as, e.g., C5 inhibitor, such as eculizumab or an eculizumab variant or a C5a inhibitor such as olendalizumab (ALXN1007) or a variant thereof, to the subject. In addition, the present disclosure relates to, inter alia, a method of treating human patients inflicted with severe coronavirus disease-2019 (severe COVID-19) who is undergoing treatment with eculizumab. The method includes measuring a level of circulating component C5b-9 (membrane attack complex), in the patient's blood sample to titrate an effective eculizumab dose for the treatment of COVID-19.

公开(公告)号：US20210388070A1

公开(公告)日：2021-12-16

申请号：US17289150

申请日：2019-10-30

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Andrew Denker ,  Rajendra Pradhan ,  Douglas L. Sheridan ,  Marc Vallee ,  Yang Dai ,  Xiang Gao

IPC: C07K16/18 ,  A61K38/47 ,  A61P7/00

Abstract: Provided herein are compositions and methods for treating a human patient with a complement-associated condition (e.g., PNH or aHUS) by subcutaneously co-administering to the patient a hyaluronidase (e.g., rHuPH20) and an anti-C5 antibody, or antigen binding fragment thereof (e.g., ravulizumab).